EUCRATES BIOMEDICAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.

On April 7, 2023, the board of directors (the "Board") of Eucrates Biomedical Acquisition Corp. (the "Company") approved the redemption of all of the outstanding ordinary shares of the Company, no par value, that were included in the Company's initial public offering (the "Public Shares"). The Company anticipates that it will not be able to consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association, and as a result the Company intends to dissolve and liquidate. The redemption of the Public Shares is expected to be completed on April 27, 2023. As of the close of business on April 26, 2023, the Company will stop trading its Public Shares, and each Public Share held at that time will represent the right to receive the redemption amount of approximately $10.00.

On April 11, 2023, the Company issued a press release announcing the foregoing. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:



Exhibit    Description
  99.1       Press Release, dated April 11, 2023
104        Cover Page Interactive Data File (formatted as Inline XBRL document).

© Edgar Online, source Glimpses